EMEA-001849-PIP02-15-M02
Key facts
| Invented name |
Bavencio
|
| Active substance |
avelumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0242/2018
|
| PIP number |
EMEA-001849-PIP02-15-M02
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Merck KGaA
Tel. +49 6151 725200 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|